Peptide Drug Conjugates Market

Peptide Drug Conjugates Market - Global Market Share, Trends, Analysis and Forecast, 2023-2032
Frequently asked questions about this report

The peptide drug conjugates market is expected to increase at a CAGR of 16% from 2023 to 2032.

The worldwide peptide therapies market is expected to be restrained by naturally occurring peptides' poor chemical and physical stability and short plasma half-life.

Based on product, the Lutathera segment had the largest market share because it is the first PDC to receive approval and it addresses a need in neuroendocrine tumours.

The global increase in cancer cases and accompanying mortality, the strong clinical pipeline of PDCs, and the uncontrolled toxicity associated with the existing small molecule chemotherapeutic treatments are the main reasons driving the market expansion.

The peptide drug conjugates market size was estimated to be US$ 575 million in 2021.